Olopatadine is an antihistamine and mast cell stabilizer that works by decreasing chemotaxis and inhibition of eosinophil activation.
The FDA approval was supported by data from two Conjunctival Allergen Challenge clinical studies that showed Pazeo 0.7% statistically and significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment vs. olopatadine 0.2% (Pataday). Pazeo solution also showed a similar safety profile with that of olopatadine 0.2%.
Pazeo will be available as a 0.7% strength solution in March 2015.
For more information call (800) 757-9785 or visit Alcon.com.